Strong Tower Advisory Services Buys Shares of 20,606 Hims & Hers Health, Inc. (NYSE:HIMS)

Strong Tower Advisory Services bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 20,606 shares of the company's stock, valued at approximately $572,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Fiduciary Alliance LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at about $1,465,000. Rhumbline Advisers increased its stake in Hims & Hers Health by 15.7% in the 1st quarter. Rhumbline Advisers now owns 597,331 shares of the company's stock valued at $17,651,000 after buying an additional 81,107 shares during the last quarter. Burr Financial Services LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at about $211,000. GAMMA Investing LLC increased its stake in Hims & Hers Health by 6,651.5% in the 1st quarter. GAMMA Investing LLC now owns 151,976 shares of the company's stock valued at $44,910,000 after buying an additional 149,725 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Hims & Hers Health by 18.8% in the 4th quarter. California State Teachers Retirement System now owns 166,337 shares of the company's stock valued at $4,022,000 after buying an additional 26,363 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In related news, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the transaction, the insider now directly owns 209,661 shares of the company's stock, valued at $7,193,468.91. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the transaction, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. The trade was a 42.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 617,367 shares of company stock valued at $25,227,888. Insiders own 13.71% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Citigroup reiterated a "sell" rating and issued a $30.00 price objective (up previously from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Needham & Company LLC raised their price target on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Price Performance

NYSE HIMS traded up $0.22 during trading on Thursday, hitting $53.83. 17,869,274 shares of the company's stock traded hands, compared to its average volume of 20,432,504. The stock has a fifty day moving average of $41.26 and a two-hundred day moving average of $36.68. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The firm has a market cap of $12.05 billion, a P/E ratio of 122.34 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the prior year, the business posted $0.05 earnings per share. The company's revenue was up 110.7% on a year-over-year basis. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.